Metastatic Urothelial Cancer Completed Phase 1 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0066157 (Metastatic Urothelial Cancer)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02826564Trial of Stereotactic Body Radiotherapy With Concurrent Pembrolizumab in Metastatic Urothelial CancerTreatment